SYGNIS AG Signs Distribution Agreement with LABGENE Scientific
News Sep 18, 2015
SYGNIS AG has announced that it has signed a distribution agreement with LABGENE Scientific for the commercialization of SYGNIS’ proprietary product portfolio in Switzerland.
Under the terms of the agreement, SYGNIS has granted LABGENE Scientific the rights to promote, market and sell all existing as well as future product lines to scientists working in genomics, proteomics and diagnostics in Switzerland.
These product lines cover the Company’s revolutionary TruePrime™ products for primer-free whole genome amplification (WGA) as well as SunScript™ thermostable reverse transcriptase kits for the translation of RNA into DNA including the newly launched SunScript™ One Step Reverse Transcriptase (RT)-PCR Kit for parallel transcription and amplification of genomic information.
LABGENE Scientific is a specialist provider offering a broad portfolio of advanced and high quality products, reagents and consumables for molecular biology laboratories and facilities as well as platforms as integrated solutions for the life science research, diagnostic laboratories and the pharmaceutical industry.
“We are very pleased about this distribution agreement for our proprietary product portfolio with LABGENE Scientific, a well established distributor in Switzerland. In addition to its very dynamic academic life science environment, Switzerland is the home to many biotechnology and pharmaceutical companies, including the biggest of the world, and an important market for our products in Europe. Today, more than 40 life science companies have their international headquarters in Switzerland,” Pilar de la Huerta, CEO and CFO of SYGNIS commented.
Huerta continued, “With its wide customer network, LABGENE Scientific is best positioned to leverage the benefits of our existing as well as future products to customers in academic and pharmaceutical molecular biology and diagnostics laboratories in Switzerland.”
Neuroblastoma Biomarker Research Advances TreatmentNews
Neuroblastoma, a childhood cancer, is treatable in less than half of aggressive cases, but new RNA biomarkers may help identify high-risk patients faster and lead to better prognosis.READ MORE
The Exercise Regime of the Future Needs to Check Your GenesNews
Forget protein bars - genes may be central to the exercise regimes of the future, as scientists track down gene changes which occur in response to exercise.READ MORE